BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 26695135)

  • 21. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
    Meher BR; Wang Y
    J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
    Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
    Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
    Chetty S; Bhakat S; Martin AJ; Soliman ME
    J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V; Tamizhselvi R; Munusami P
    J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
    Appadurai R; Senapati S
    Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into the in silico prediction of HIV protease resistance to nelfinavir.
    Antunes DA; Rigo MM; Sinigaglia M; de Medeiros RM; Junqueira DM; Almeida SE; Vieira GF
    PLoS One; 2014; 9(1):e87520. PubMed ID: 24498124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
    Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
    Sherry D; Worth R; Ismail ZS; Sayed Y
    J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
    Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
    J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
    Liu F; Kovalevsky AY; Louis JM; Boross PI; Wang YF; Harrison RW; Weber IT
    J Mol Biol; 2006 May; 358(5):1191-9. PubMed ID: 16569415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
    Chen J; Peng C; Wang J; Zhu W
    Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
    Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
    J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.